Clinical Trials | January 15, 2026
Boehringer Ingelheim and Jazz Pharma team up on novel HER2-positive breast cancer therapy
The partnership will launch a Phase 1b cohort within Boehringer’s ongoing Beamion-BCGC1 trial
The partnership will launch a Phase 1b cohort within Boehringer’s ongoing Beamion-BCGC1 trial
The therapy is mutation-agnostic and aims to overcome limitations of existing EGFR-targeting drugs by concentrating degradation in tumors while sparing healthy tissue
Kelun-Biotech and Crescent Biopharma forged a collaboration covering SKB105/CR-003 and SKB118, a PD-1 x VEGF bispecific antibody also known as CR-001
The company plans to use the newly secured funding to expand the indications of its Grabody platform into high-unmet-need areas
Full approval will depend on verification of clinical benefit in a confirmatory trial
The pharmaceutical giant now expects 2026 revenues to land between $59.5 billion and $62.5 billion
The Phase 2 study tested two dose levels of pumitamig alongside four standard chemotherapy regimens across first
This collaboration sets the stage for WuXi Biologics’ first integrated CRDMO center in the region
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
GV20 received an upfront payment and is eligible for additional milestone payments
Subscribe To Our Newsletter & Stay Updated
